News · Decision pending

CagriSema FDA decision expected in Q4 2026; not approved as of November 20, 2026

Key numbers

Status
FDA decision expected in Q4 2026, per Novo Nordisk. Not approved as of November 20, 2026. In the REDEFINE 1 trial, CagriSema produced 20.4% weight loss at 68 weeks against 3.0% on placebo.
Date
Filed with the FDA on December 18, 2025. Decision timing restated in Novo's Q3 report on November 4, 2026.
Announced by
Novo Nordisk: Novo Nordisk Q3 2026 report (SEC filing)
Eduard Cristea
Eduard Cristea
Published:
Regulatory review binders and a pen on an office desk

What happened

On December 18, 2025, Novo Nordisk filed a New Drug Application with the FDA for CagriSema, a once-weekly injection that combines cagrilintide, a long-acting amylin analogue, with semaglutide, the ingredient in Wegovy (Novo Nordisk).

The filing rests on the REDEFINE 1 and REDEFINE 2 trials. In REDEFINE 1, 3,417 adults with obesity or overweight lost 20.4% of their body weight at 68 weeks on CagriSema, against 3.0% on placebo, counting everyone who started. Counting only people who stayed on treatment, it was 22.7% against 2.3%. Stopping because of side effects was 5.9% on CagriSema against 3.5% on placebo; nausea was reported by 55% against 12.6%.

Novo's Q3 2026 report, filed on November 4, 2026, lists "CagriSema US decision" as a Q4 2026 milestone, and its CEO said Novo is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval" (Novo Nordisk). No FDA decision has been announced as of November 20, 2026, and no public decision date (PDUFA date) has been published.

What this means for cost

CagriSema has no US price because it is not approved. Its semaglutide half is already available as Wegovy and as compounded semaglutide, at the prices on our records below.

Cash prices on our records
OptionCash price on our recordRead
Wegovy (semaglutide), Novo NordiskPen: $199 a month for the first 2 fills at 0.25 mg or 0.5 mg for new patients, through December 31, 2026, then $349. Pill: $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg.Maker's page, Nov 6, 2026
EmbodyCompounded semaglutide$79/mo, medication plus recorded program feeRecorded Nov 6, 2026
CoreAge RxCompounded semaglutide$79/mo, medication plus recorded program feeRecorded Nov 6, 2026
AgelessRxCompounded semaglutide$139/mo, medication plus recorded program feeDate not recorded

Compounded rows are the lowest recorded monthly subtotals among active listings, sorted by price: medication plus any recorded program fee, with other costs such as labs or shipping not included. Compounded medications are not FDA-approved and are not the brand products. Your prescriber decides which drug and strength fit you.

What happens next

  1. Q4 2026 (by December 31, 2026)

    FDA decision expected, per Novo Nordisk. We will update this page the day it is announced.

  2. Early 2027

    Novo says it is preparing a US launch, subject to approval.

  3. H1 2027

    Phase 3 results from REDEFINE 11, a longer trial, per Novo's milestone table.

Sources

  1. Novo Nordisk, CagriSema FDA filing (Dec 18, 2025), read Nov 20, 2026
  2. Novo Nordisk, Q3 2026 financial report, Form 6-K (Nov 4, 2026), read Nov 20, 2026

Embody

from $49/mo, 12-month plan

Visit Embody